---
document_datetime: 2025-12-29 14:06:31
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/nyvepria.html
document_name: nyvepria.html
version: success
processing_time: 0.1066963
conversion_datetime: 2025-12-30 03:11:46.871888
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Nyvepria

[RSS](/en/individual-human-medicine.xml/67367)

##### Authorised

This medicine is authorised for use in the European Union

pegfilgrastim Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Nyvepria](#news-on)
- [Related content](#related-content-916)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Nyvepria is a medicine used in cancer patients to help with neutropenia (low levels of neutrophils, a type of white blood cell), which is a common side effect of cancer chemotherapy and can leave patients vulnerable to infections.

It is given specifically to reduce the duration of neutropenia and prevent febrile neutropenia (when neutropenia is accompanied by fever due to an infection).

Nyvepria is not intended for use in patients with the blood cancer chronic myeloid leukaemia or with myelodysplastic syndromes (conditions in which large numbers of abnormal blood cells are produced, which can develop into leukaemia).

Nyvepria is a 'biosimilar medicine'. This means that Nyvepria is highly similar to another biological medicine (the 'reference medicine') that is already authorised in the EU. The reference medicine for Nyvepria is Neulasta.

Nyvepria contains the active substance pegfilgrastim.

Expand section

Collapse section

## How is Nyvepria used?

Nyvepria can only be obtained with a prescription and treatment should be started and supervised by a doctor who has experience in the treatment of cancer or blood disorders. It is available as a prefilled syringe containing a solution for injection under the skin. Nyvepria is given as a single dose of 6 mg injected under the skin at least 24 hours after the end of each cycle of chemotherapy. Patients can inject themselves if they have been trained appropriately.

For more information about using Nyvepria, see the package leaflet or contact your doctor or pharmacist.

## How does Nyvepria work?

The active substance in Nyvepria, pegfilgrastim, is a form of filgrastim, which is very similar to a human protein called granulocyte-colony-stimulating factor (G-CSF). Filgrastim works by encouraging the bone marrow to produce more white blood cells, increasing white blood cell counts and so treating neutropenia.

Filgrastim has been available in other medicines in the EU for a number of years. In Nyvepria, filgrastim has been 'pegylated' (attached to a chemical called polyethylene glycol). This slows down the removal of filgrastim from the body, allowing the medicine to be given less often.

## What benefits of Nyvepria have been shown in studies?

Laboratory studies comparing Nyvepria with Neulasta have shown that the active substance in Nyvepria is highly similar to that in Neulasta in terms of structure, purity and biological activity. Studies have also shown that giving Nyvepria produces similar levels of the active substance in the body to giving Neulasta.

Because Nyvepria is a biosimilar medicine, the studies on effectiveness and safety of pegfilgrastim carried out with Neulasta do not all need to be repeated for Nyvepria.

## What are the risks associated with Nyvepria?

The safety of Nyvepria has been evaluated, and on the basis of all the studies carried out the side effects of the medicine are considered to be comparable to those of the reference medicine Neulasta.

The most common side effect with Nyvepria (which may affect more than 1 in 10 people) is pain in the bones. Pain in muscles is also common. For the full list of side effects and restrictions with Nyvepria, see the package leaflet.

## Why is Nyvepria authorised in the EU?

The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Nyvepria has a highly similar structure, purity and biological activity to Neulasta and is distributed in the body in the same way.

All these data were considered sufficient to conclude that Nyvepria will behave in the same way as Neulasta in terms of effectiveness and safety in its authorised uses. Therefore, the Agency's view was that, as for Neulasta, the benefits of Nyvepria outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Nyvepria?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Nyvepria have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Nyvepria are continuously monitored. Side effects reported with Nyvepria are carefully evaluated and any necessary action taken to protect patients.

## Other information about Nyvepria

Nyvepria received a marketing authorisation valid throughout the EU on 18 November 2020.

Nyvepria : EPAR - Medicine overview

Reference Number: EMA/559330/2020

English (EN) (120.63 KB - PDF)

**First published:** 23/11/2020

[View](/en/documents/overview/nyvepria-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-932)

български (BG) (135.33 KB - PDF)

**First published:**

23/11/2020

[View](/bg/documents/overview/nyvepria-epar-medicine-overview_bg.pdf)

español (ES) (110.68 KB - PDF)

**First published:**

23/11/2020

[View](/es/documents/overview/nyvepria-epar-medicine-overview_es.pdf)

čeština (CS) (132.58 KB - PDF)

**First published:**

23/11/2020

[View](/cs/documents/overview/nyvepria-epar-medicine-overview_cs.pdf)

dansk (DA) (109.19 KB - PDF)

**First published:**

23/11/2020

[View](/da/documents/overview/nyvepria-epar-medicine-overview_da.pdf)

Deutsch (DE) (113.76 KB - PDF)

**First published:**

23/11/2020

[View](/de/documents/overview/nyvepria-epar-medicine-overview_de.pdf)

eesti keel (ET) (97.41 KB - PDF)

**First published:**

23/11/2020

[View](/et/documents/overview/nyvepria-epar-medicine-overview_et.pdf)

ελληνικά (EL) (135.06 KB - PDF)

**First published:**

23/11/2020

[View](/el/documents/overview/nyvepria-epar-medicine-overview_el.pdf)

français (FR) (111.64 KB - PDF)

**First published:**

23/11/2020

[View](/fr/documents/overview/nyvepria-epar-medicine-overview_fr.pdf)

hrvatski (HR) (130.03 KB - PDF)

**First published:**

23/11/2020

[View](/hr/documents/overview/nyvepria-epar-medicine-overview_hr.pdf)

italiano (IT) (108.75 KB - PDF)

**First published:**

23/11/2020

[View](/it/documents/overview/nyvepria-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (112.92 KB - PDF)

**First published:**

23/11/2020

[View](/lv/documents/overview/nyvepria-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (129.07 KB - PDF)

**First published:**

23/11/2020

[View](/lt/documents/overview/nyvepria-epar-medicine-overview_lt.pdf)

magyar (HU) (129.49 KB - PDF)

**First published:**

23/11/2020

[View](/hu/documents/overview/nyvepria-epar-medicine-overview_hu.pdf)

Malti (MT) (131.57 KB - PDF)

**First published:**

23/11/2020

[View](/mt/documents/overview/nyvepria-epar-medicine-overview_mt.pdf)

Nederlands (NL) (111.21 KB - PDF)

**First published:**

23/11/2020

[View](/nl/documents/overview/nyvepria-epar-medicine-overview_nl.pdf)

polski (PL) (136.21 KB - PDF)

**First published:**

23/11/2020

[View](/pl/documents/overview/nyvepria-epar-medicine-overview_pl.pdf)

português (PT) (111.14 KB - PDF)

**First published:**

23/11/2020

[View](/pt/documents/overview/nyvepria-epar-medicine-overview_pt.pdf)

română (RO) (128.6 KB - PDF)

**First published:**

23/11/2020

[View](/ro/documents/overview/nyvepria-epar-medicine-overview_ro.pdf)

slovenčina (SK) (130.9 KB - PDF)

**First published:**

23/11/2020

[View](/sk/documents/overview/nyvepria-epar-medicine-overview_sk.pdf)

slovenščina (SL) (128.81 KB - PDF)

**First published:**

23/11/2020

[View](/sl/documents/overview/nyvepria-epar-medicine-overview_sl.pdf)

Suomi (FI) (107.42 KB - PDF)

**First published:**

23/11/2020

[View](/fi/documents/overview/nyvepria-epar-medicine-overview_fi.pdf)

svenska (SV) (107.83 KB - PDF)

**First published:**

23/11/2020

[View](/sv/documents/overview/nyvepria-epar-medicine-overview_sv.pdf)

Nyvepria : EPAR - Risk-management-plan summary

English (EN) (653.18 KB - PDF)

**First published:** 23/11/2020

[View](/en/documents/rmp-summary/nyvepria-epar-risk-management-plan-summary_en.pdf)

## Product information

Nyvepria : EPAR - Product information

English (EN) (1.31 MB - PDF)

**First published:** 23/11/2020

**Last updated:** 24/11/2025

[View](/en/documents/product-information/nyvepria-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-30)

български (BG) (984.78 KB - PDF)

**First published:**

23/11/2020

**Last updated:**

24/11/2025

[View](/bg/documents/product-information/nyvepria-epar-product-information_bg.pdf)

español (ES) (730.48 KB - PDF)

**First published:**

23/11/2020

**Last updated:**

24/11/2025

[View](/es/documents/product-information/nyvepria-epar-product-information_es.pdf)

čeština (CS) (874.08 KB - PDF)

**First published:**

23/11/2020

**Last updated:**

24/11/2025

[View](/cs/documents/product-information/nyvepria-epar-product-information_cs.pdf)

dansk (DA) (833.07 KB - PDF)

**First published:**

23/11/2020

**Last updated:**

24/11/2025

[View](/da/documents/product-information/nyvepria-epar-product-information_da.pdf)

Deutsch (DE) (909.96 KB - PDF)

**First published:**

23/11/2020

**Last updated:**

24/11/2025

[View](/de/documents/product-information/nyvepria-epar-product-information_de.pdf)

eesti keel (ET) (1.2 MB - PDF)

**First published:**

23/11/2020

**Last updated:**

24/11/2025

[View](/et/documents/product-information/nyvepria-epar-product-information_et.pdf)

ελληνικά (EL) (791.74 KB - PDF)

**First published:**

23/11/2020

**Last updated:**

24/11/2025

[View](/el/documents/product-information/nyvepria-epar-product-information_el.pdf)

français (FR) (1.02 MB - PDF)

**First published:**

23/11/2020

**Last updated:**

24/11/2025

[View](/fr/documents/product-information/nyvepria-epar-product-information_fr.pdf)

hrvatski (HR) (862.77 KB - PDF)

**First published:**

23/11/2020

**Last updated:**

24/11/2025

[View](/hr/documents/product-information/nyvepria-epar-product-information_hr.pdf)

íslenska (IS) (814.55 KB - PDF)

**First published:**

23/11/2020

**Last updated:**

24/11/2025

[View](/is/documents/product-information/nyvepria-epar-product-information_is.pdf)

italiano (IT) (881.33 KB - PDF)

**First published:**

23/11/2020

**Last updated:**

24/11/2025

[View](/it/documents/product-information/nyvepria-epar-product-information_it.pdf)

latviešu valoda (LV) (986.87 KB - PDF)

**First published:**

23/11/2020

**Last updated:**

24/11/2025

[View](/lv/documents/product-information/nyvepria-epar-product-information_lv.pdf)

lietuvių kalba (LT) (876.1 KB - PDF)

**First published:**

23/11/2020

**Last updated:**

24/11/2025

[View](/lt/documents/product-information/nyvepria-epar-product-information_lt.pdf)

magyar (HU) (837.61 KB - PDF)

**First published:**

23/11/2020

**Last updated:**

24/11/2025

[View](/hu/documents/product-information/nyvepria-epar-product-information_hu.pdf)

Malti (MT) (921.19 KB - PDF)

**First published:**

23/11/2020

**Last updated:**

24/11/2025

[View](/mt/documents/product-information/nyvepria-epar-product-information_mt.pdf)

Nederlands (NL) (1016.34 KB - PDF)

**First published:**

23/11/2020

**Last updated:**

24/11/2025

[View](/nl/documents/product-information/nyvepria-epar-product-information_nl.pdf)

norsk (NO) (785.07 KB - PDF)

**First published:**

23/11/2020

**Last updated:**

24/11/2025

[View](/no/documents/product-information/nyvepria-epar-product-information_no.pdf)

polski (PL) (1.01 MB - PDF)

**First published:**

23/11/2020

**Last updated:**

24/11/2025

[View](/pl/documents/product-information/nyvepria-epar-product-information_pl.pdf)

português (PT) (879.49 KB - PDF)

**First published:**

23/11/2020

**Last updated:**

24/11/2025

[View](/pt/documents/product-information/nyvepria-epar-product-information_pt.pdf)

română (RO) (858.72 KB - PDF)

**First published:**

23/11/2020

**Last updated:**

24/11/2025

[View](/ro/documents/product-information/nyvepria-epar-product-information_ro.pdf)

slovenčina (SK) (917.94 KB - PDF)

**First published:**

23/11/2020

**Last updated:**

24/11/2025

[View](/sk/documents/product-information/nyvepria-epar-product-information_sk.pdf)

slovenščina (SL) (991.43 KB - PDF)

**First published:**

23/11/2020

**Last updated:**

24/11/2025

[View](/sl/documents/product-information/nyvepria-epar-product-information_sl.pdf)

Suomi (FI) (877.78 KB - PDF)

**First published:**

23/11/2020

**Last updated:**

24/11/2025

[View](/fi/documents/product-information/nyvepria-epar-product-information_fi.pdf)

svenska (SV) (958.89 KB - PDF)

**First published:**

23/11/2020

**Last updated:**

24/11/2025

[View](/sv/documents/product-information/nyvepria-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** R/0000249250 04/08/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Nyvepria : EPAR - All authorised presentations

English (EN) (25.87 KB - PDF)

**First published:** 23/11/2020

[View](/en/documents/all-authorised-presentations/nyvepria-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-261)

български (BG) (27.59 KB - PDF)

**First published:**

23/11/2020

[View](/bg/documents/all-authorised-presentations/nyvepria-epar-all-authorised-presentations_bg.pdf)

español (ES) (25.6 KB - PDF)

**First published:**

23/11/2020

[View](/es/documents/all-authorised-presentations/nyvepria-epar-all-authorised-presentations_es.pdf)

čeština (CS) (26.89 KB - PDF)

**First published:**

23/11/2020

[View](/cs/documents/all-authorised-presentations/nyvepria-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (34.04 KB - PDF)

**First published:**

23/11/2020

[View](/da/documents/all-authorised-presentations/nyvepria-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (27.52 KB - PDF)

**First published:**

23/11/2020

[View](/de/documents/all-authorised-presentations/nyvepria-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (24.4 KB - PDF)

**First published:**

23/11/2020

[View](/et/documents/all-authorised-presentations/nyvepria-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (26.29 KB - PDF)

**First published:**

23/11/2020

[View](/el/documents/all-authorised-presentations/nyvepria-epar-all-authorised-presentations_el.pdf)

français (FR) (25.64 KB - PDF)

**First published:**

23/11/2020

[View](/fr/documents/all-authorised-presentations/nyvepria-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (25.76 KB - PDF)

**First published:**

23/11/2020

[View](/hr/documents/all-authorised-presentations/nyvepria-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (25.96 KB - PDF)

**First published:**

23/11/2020

[View](/is/documents/all-authorised-presentations/nyvepria-epar-all-authorised-presentations_is.pdf)

italiano (IT) (25.02 KB - PDF)

**First published:**

23/11/2020

[View](/it/documents/all-authorised-presentations/nyvepria-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (26.35 KB - PDF)

**First published:**

23/11/2020

[View](/lv/documents/all-authorised-presentations/nyvepria-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (25.91 KB - PDF)

**First published:**

23/11/2020

[View](/lt/documents/all-authorised-presentations/nyvepria-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (26.65 KB - PDF)

**First published:**

23/11/2020

[View](/hu/documents/all-authorised-presentations/nyvepria-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (26.66 KB - PDF)

**First published:**

23/11/2020

[View](/mt/documents/all-authorised-presentations/nyvepria-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (25.66 KB - PDF)

**First published:**

23/11/2020

[View](/nl/documents/all-authorised-presentations/nyvepria-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (26.9 KB - PDF)

**First published:**

23/11/2020

[View](/no/documents/all-authorised-presentations/nyvepria-epar-all-authorised-presentations_no.pdf)

polski (PL) (27.07 KB - PDF)

**First published:**

23/11/2020

[View](/pl/documents/all-authorised-presentations/nyvepria-epar-all-authorised-presentations_pl.pdf)

português (PT) (26.68 KB - PDF)

**First published:**

23/11/2020

[View](/pt/documents/all-authorised-presentations/nyvepria-epar-all-authorised-presentations_pt.pdf)

română (RO) (25.57 KB - PDF)

**First published:**

23/11/2020

[View](/ro/documents/all-authorised-presentations/nyvepria-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (26.68 KB - PDF)

**First published:**

23/11/2020

[View](/sk/documents/all-authorised-presentations/nyvepria-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (25.58 KB - PDF)

**First published:**

23/11/2020

[View](/sl/documents/all-authorised-presentations/nyvepria-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (24.32 KB - PDF)

**First published:**

23/11/2020

[View](/fi/documents/all-authorised-presentations/nyvepria-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (25.66 KB - PDF)

**First published:**

23/11/2020

[View](/sv/documents/all-authorised-presentations/nyvepria-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Nyvepria Active substance pegfilgrastim International non-proprietary name (INN) or common name pegfilgrastim Anatomical therapeutic chemical (ATC) code L03AA13

### Pharmacotherapeutic group

Immunostimulants

### Therapeutic indication

Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

## Authorisation details

EMA product number EMEA/H/C/005085

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the 'reference medicine'. For more information, see [Biosimilar medicines](/node/68323) .

Marketing authorisation holder

Pfizer Europe MA EEIG

Boulevard de la Plaine 17

Opinion adopted 17/09/2020 Marketing authorisation issued 18/11/2020 Revision 8

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Nyvepria : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (136.18 KB - PDF)

**First published:** 24/11/2025

[View](/en/documents/procedural-steps-after/nyvepria-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Nyvepria : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (118.74 KB - PDF)

**First published:** 23/03/2021

**Last updated:** 24/11/2025

[View](/en/documents/procedural-steps-after/nyvepria-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Nyvepria : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/603684/2020

English (EN) (2.57 MB - PDF)

**First published:** 23/11/2020

[View](/en/documents/assessment-report/nyvepria-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Nyvepria

Adopted

Reference Number: EMA/CHMP/447855/2020

English (EN) (128.01 KB - PDF)

**First published:** 18/09/2020

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-nyvepria_en.pdf)

#### News on Nyvepria

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-september-2020) 18/09/2020

#### Related content

- [Biosimilar medicines: Overview](/en/human-regulatory-overview/biosimilar-medicines-overview)

#### Topics

- [Biosimilars](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A45)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 24/11/2025

## Share this page

[Back to top](#main-content)